Harbour BioMed-B (02142.HK)-Backed Enkay Therapeutics Completes Nearly RMB 100 Million Series A+++ Financing

Zhitong Finance APP reported that Harbour BioMed-B (02142) announced its invested company, Shanghai EnCay Cell Tech Co., Ltd. (EnCay Therapeutics), has recently completed its A+++ round of financing. This round of financing involved multiple investors and raised nearly RMB 100 million. The proceeds will be used to advance clinical trials of its core NK cell therapy product candidates and support the development of its product pipeline.

This successful financing reflects the continuous breakthroughs achieved by Enkaiphar in the development of NK cell therapy, demonstrating investors' confidence in its innovative immunotherapy platform. The funds raised will provide significant support for accelerating clinical translation.

It is reported that Enkaipharma is a biotechnology company focusing on the research and development of innovative NK cell therapy technologies. In 2024, one of its NK cell product candidates received approval for an Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), and another NK cell product candidate received IND approval from the National Medical Products Administration (NMPA) of China.

In June 2021, the company invested in Enkaipharma through its subsidiary, Harbour BioMed (Shanghai) Technology Development Co., Ltd., as a co-founder. As of December 31, 2024, the company holds 10.90% of Enkaipharma's total equity through Harbour BioMed Shanghai.